EMPG:NASDAQEmpro Group Inc. Analysis
Data as of 2026-06-16 - not real-time
$17.36
Latest Price
8/10Risk
Risk Level: High
Executive Summary
EMPG is trading at $17.36, precisely on its 20‑day and 50‑day SMA, but technical signals are mixed: the 14‑day RSI sits at 71 (deeply overbought) and the MACD histogram is negative, indicating a bearish tilt. Valuation metrics are extreme, with a trailing P/E of 192.9 versus an industry average of 24.7, a P/B of 17.05, and a DCF‑derived fair value of only $0.24, suggesting the stock is vastly overvalued. The company boasts impressive profitability—gross margin of 61.8%, operating margin of 36.1% and a profit margin of 13.7%—and revenue has more than doubled year‑over‑year, yet free cash flow is negative and debt‑to‑equity is near 100%, raising sustainability concerns.
Compounding the financial picture, EMPG recently received a Nasdaq non‑compliance notice for failing to file its Form 20‑F and is under investigation for potential securities fraud, elevating regulatory and corporate‑governance risk. The stock’s beta is low (0.15) and volatility over the past 30 days is zero, but trading volume is effectively nil, indicating poor liquidity. These combined factors point to a highly overvalued, risk‑laden equity that warrants caution.
Compounding the financial picture, EMPG recently received a Nasdaq non‑compliance notice for failing to file its Form 20‑F and is under investigation for potential securities fraud, elevating regulatory and corporate‑governance risk. The stock’s beta is low (0.15) and volatility over the past 30 days is zero, but trading volume is effectively nil, indicating poor liquidity. These combined factors point to a highly overvalued, risk‑laden equity that warrants caution.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Bearish MACD and overbought RSI
- Nasdaq non‑compliance and fraud investigation
- Extreme valuation multiples vs DCF fair value
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong operating margins and revenue growth
- Resolution of compliance issues could unlock value
- Continued high debt and negative free cash flow
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained demand in medical distribution sector
- Potential for operational turnaround if governance improves
- Persistently high valuation and liquidity constraints
Key Metrics & Analysis
Financial Health
Revenue Growth141.60%
Profit Margin13.70%
P/E Ratio192.9
ROE66.26%
ROA16.42%
Debt/Equity99.92
P/B Ratio17.1
Op. Cash Flow$129.7K
Free Cash Flow$-205317
Industry P/E24.7
Technical Analysis
TrendNeutral
RSI71.4
Support$17.36
Resistance$17.36
MA 20$17.36
MA 50$17.36
MA 200$16.80
MACDBearish
VolumeStable
Fear & Greed Index92.13
Valuation
Fair Value$0.24
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.15
0Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.